If you're looking for stocks that combine solid dividends and growth potential, drugmakers Bristol-Myers Squibb, AbbVie, and Lilly might be right for you.
Cash generated by Bristol's operations is spread pretty thin. Should shareholders brace for another years-long dividend freeze -- or worse?
Despite a lackluster market, these stocks rose. Find out why.
Bristol-Myers Squibb knocks it out of the park with its Q3 results. Here are the key takeaways from the company's impressive performance.
Healthcare bargains abound for patient long-term investors.
Is Opdivo on track to Opd-imize your portfolio?
It's playing against Big Pharma -- and its kidney cancer treatment Cabometyx just might win.
Looking for Big Pharma bargains? Mallinckrodt, Bayer, and Bristol-Myers Squibb might be right up your alley.
These three value stocks may be down, but they're far from out.
A surprising failure for Opdivo opens the door for a competitor to grab significant market share.